Skip to main content

Table 2 Baseline characteristics of 33 patients receiving sirolimus gel for facial angiofibroma associated with tuberous sclerosis complex

From: Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex

CharacteristicsNumber%
Median age (range)25 (14–55) 
Sex
 Male/Female17/16 
ECOG performance status
 0/1/224/8/1 
Major features
  ≥ 3 Hypomelanotic macules2061
  ≥ 2 Ungual fibromas1855
 Shagreen patch1752
 Multiple retinal hamartomas618
 Cortical dysplasias2576
 Subependymal nodules1958
 Subependymal giant cell astrocytoma515
 Cardiac rhabdomyoma412
 Lung lymphangioleiomyomatosis618
  ≥ 2 Renal angiomyolipomas3194
Minor features
  ≥ 3 Dental enamel pits1030
  ≥ 2 Intraoral fibromas618
 Retinal achromic patch515
 Multiple renal cysts26
 Nonrenal hamartomas13